On December 18, 2023, Neurogene Inc. closed the transaction. The company has now issued 36,934,089 common shares and 23,964,846 pre-funded warrants for gross proceeds of approximately $95 million. At the closing, the securities were converted into shares of company's common Stock and $0.000001 pre-funded warrants at a rate of 0.0756 shares of common stock per share, and 0.0756 $0.000001 pre-funded warrants for each company's prefunded warrant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.55 USD | +2.97% | -7.04% | +62.80% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
803 USD | +1.60% | +2.82% | 117B | ||
31.55 USD | +2.97% | -7.04% | 394M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.80% | 394M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neurogene Inc. announced that it has received $95 million in funding from a group of investors